Diabetic macular edema (DME) is the main cause of visual impairment in patients with diabetic retinopathy (DR) and anti‐vascular endothelial growth factor (anti‐VEGF) therapy is the standard of care for DME [1]. The gene discussed is VEGFA; the disease is diabetic macular edema.